INTERNATIONAL FACULTY
Professor David F.
Penson
Chair, Department of Urology
Vanderbilt University Medical Center, United States
David F. Penson, MD, MPH is the Hamilton and Howd Chair in Urologic Oncology, Director of the Center for Surgical Quality and Outcomes Research and Professor and Chair, Department of Urology at Vanderbilt University Medical Center. He obtained his MD from Boston University and completed his urology residency at UCLA Medical Center in Los Angeles....
Mr James Hill
Oliver Sartor, M.D., is a medical oncologist in the Division of Medical Oncology in the
Department of Oncology at Mayo Clinic in Rochester, Minnesota. Dr. Sartor serves as
chair of the Genitourinary Cancer Disease Group and director of Radiopharmaceutical
Clinical Trials across the enterprise for Mayo Clinic Comprehensive Cancer Center. Dr.
Sartor joined the staff of Mayo Clinic in April 2023.
After receiving his M.D. from Tulane University School of Medicine in New Orleans, Dr.
Sartor completed his internal medicine residency, followed by a fellowship at the
National Cancer Institute in Bethesda, Maryland, where he was junior faculty. He later
returned to New Orleans, eventually becoming chief of the Hematology/Oncology Section
and director of the Stanley S. Scott Cancer Center at Louisiana State University Health
Sciences Center and co-director of the Louisiana Cancer Research Consortium. He later
joined the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute
and Harvard Medical School in Boston before returning to Tulane University as the
Laborde Professor for Cancer Research in the departments of Medicine and Urology,
medical director of the Tulane Cancer Center, and associate dean for Oncology for the
Tulane University School of Medicine.
Dr. Sartor has focused predominantly on clinical and translational aspects of prostate
cancer. He has published over 500 peer-reviewed manuscripts and established
multidisciplinary collaborations with urology, nuclear medicine and radiation oncology.
He was chair of the Department of Defense Integration Panel for Prostate Cancer and was
a member of the Board of Scientific Counselors at the National Cancer Institute. He has
been a principal or co-principal investigator on four pivotal multi-institutional trials
leading to Food and Drug Administration approvals for new drugs to treat advanced
prostate cancer. He is vice chair of the Genitourinary Cancer Committee for NRG
Oncology.
Professor David F. Penson
David F. Penson, MD, MPH is the Hamilton and Howd Chair in Urologic Oncology, Director of the Center for Surgical Quality and Outcomes Research and Professor and Chair, Department of Urology at Vanderbilt University Medical Center. He obtained his MD from Boston University and completed his urology residency at UCLA Medical Center in Los Angeles. He then was awarded a Robert Wood Johnson Clinical Scholar fellowship at Yale University and also obtained an MPH at Yale. He currently maintains a clinical practice in urologic oncology at the Vanderbilt-Ingram Cancer Center. His specific research interests include the comparative effectiveness of treatment options in localized prostate cancer and the impact of the disease and its treatment on patients’ quality of life. He has received federal grant funding from the National Cancer Institute, the US Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention and the Patient-Centered Outcomes Research Institute. His work has been published in various high-profile journals, including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. He previously chaired the National Institutes of Health’s Health Services Outcomes and Delivery (HSOD) study section, which reviews almost all health services research grant submitted to the NIH. He also maintains a strong interest in health policy and quality improvement. He currently serves as the Secretary of the American Urological Association.